Doptelet (avatrombopag) is a thrombopoietin receptor agonist.
Doptelet is specifically indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Doptelet is supplied as a tablet for oral administration. Begin Doptelet dosing 10-13 days prior to the scheduled procedure. The recommended daily dose of Doptelet is based on the patient’s platelet count prior to the scheduled procedure (see below). Patients should undergo their procedure 5 to 8 days after the last dose of Doptelet. Doptelet should be taken orally once daily for 5 consecutive days with food. In the case of a missed dose, patients should take the next dose of Doptelet as soon as they remember. Patients should not take two doses at one time to make up for a missed dose and should take the next dose at the usual time the next day; all five days of dosing should be completed.
Recommended Dose and Duration:
Platelet Count (x109/L): Less than 40 Once Daily Dose; 60 mg (3 tablets) for 5 days
Platelet Count (x109/L): 40 to less than 50 Once Daily Dose: 40 mg (2 tablets) for 5 days
The FDA approval of Doptelet was based on two trials, (ADAPT-1 and ADAPT-2) involving 435 patients with chronic liver disease and severe thrombocytopenia who were scheduled to undergo a procedure that would typically require platelet transfusion. The trials investigated two dose levels of Doptelet administered orally over five days as compared to placebo. The trial results showed that for both dose levels of Doptelet, a higher proportion of patients had increased platelet counts and did not require platelet transfusion or any rescue therapy on the day of the procedure and up to seven days following the procedure as compared to those treated with placebo. Percentage of Responders: ADAPT-1: 66% vs. 23% and ADAPT-2: 69% vs. 35%.
Adverse effects associated with the use of Doptelet may include, but are not limited to, the following:
Doptelet (avatrombopag) is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production.
For additional information regarding Doptelet or thrombocytopenia, please visit https://doptelet.com/